Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jamila Fruchart-Najib

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Drug News & Perspectives|April 22, 2006
Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosisHeidelinde Jakel, Jamila Fruchart-Najib, Jean-Charles Fruchart
Current Atherosclerosis Reports|July 17, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib
Current Atherosclerosis Reports|January 4, 2021
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib, et al.
Clinical Chemistry and Laboratory Medicine|July 20, 2007
Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndromeLoredan Stefan Niculescu, Jamila Fruchart-Najib, Jean-Charles Fruchart, et al.
Annals of Medicine|February 2, 2006
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?Heidelinde Jakel, Maxime Nowak, Audrey Helleboid-Chapman, et al.
Atherosclerosis|July 26, 2005
Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patientsValérie Pruneta-Deloche, Gabriel Ponsin, Laure Groisne, et al.
Diabetologia|May 3, 2005
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetesAnne Hiukka, Jamila Fruchart-Najib, Eeva Leinonen, et al.
Diabetes Care|May 9, 2007
The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activityJuhani Kahri, Jamila Fruchart-Najib, Niina Matikainen, et al.
Circulation Research|July 29, 2008
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemiaRoxane M Mansouri, Eric Baugé, Philippe Gervois, et al.
Cell Research|June 15, 2006
Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cellsAudrey Helleboid-Chapman, Stéphane Helleboid, Heidelinde Jakel, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Drug News & Perspectives|April 22, 2006
Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosisHeidelinde Jakel, Jamila Fruchart-Najib, Jean-Charles Fruchart
Current Atherosclerosis Reports|July 17, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib
Current Atherosclerosis Reports|January 4, 2021
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib, et al.
Clinical Chemistry and Laboratory Medicine|July 20, 2007
Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndromeLoredan Stefan Niculescu, Jamila Fruchart-Najib, Jean-Charles Fruchart, et al.
Annals of Medicine|February 2, 2006
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?Heidelinde Jakel, Maxime Nowak, Audrey Helleboid-Chapman, et al.
Atherosclerosis|July 26, 2005
Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patientsValérie Pruneta-Deloche, Gabriel Ponsin, Laure Groisne, et al.
Diabetologia|May 3, 2005
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetesAnne Hiukka, Jamila Fruchart-Najib, Eeva Leinonen, et al.
Diabetes Care|May 9, 2007
The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activityJuhani Kahri, Jamila Fruchart-Najib, Niina Matikainen, et al.
Circulation Research|July 29, 2008
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemiaRoxane M Mansouri, Eric Baugé, Philippe Gervois, et al.
Cell Research|June 15, 2006
Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cellsAudrey Helleboid-Chapman, Stéphane Helleboid, Heidelinde Jakel, et al.
Pageof 3